#Italy #Rome #Haier Biomedical #European Summit #Life Science Innovation

Haier Biomedical's European Partner Summit in Rome

Haier Biomedical recently hosted a significant summit for its European partners in Rome, themed "Advancing Together - Sharing the Future of Biomedical Innovation." The event drew in 37 regional partners and industry leaders from 23 European nations, highlighting Haier's enduring commitment to the continent and its strategic evolution in laboratory solutions.

A Strategic Shift Towards Localized Solutions

During the summit, Enrique Wang, Haier Biomedical's Global Market Director, reaffirmed the company's ambitious vision to achieve over 50% of its global revenue from international markets by 2027, along with more than half of its revenue coming from non-refrigeration segments by 2028. He emphasized Europe's strategic importance within the company's globalization roadmap, which operates under the guiding principle of "In Europe, for Europe." This ensures products, services, and support are tailored to meet regional regulatory standards and customer expectations.

Spotlight on Innovation in 2026

Semir Selimovic, Director for Northern, Central, and Eastern Europe, elaborated on the company's 2026 European strategy, advocating for ongoing investments in local sales and product expertise to ensure agility and effective execution in key markets. Europe is rapidly becoming a top growth region for Haier, bolstered by expanding local teams and an increasingly diverse product range.

Among the newly launched products, the XJ-III plasma apheresis system captured considerable attention, achieving compliance with the EU's Medical Device Regulation (MDR). This compliance exemplifies Haier Biomedical's commitment to meeting Europe's stringent regulatory demands, boosting its reputation in blood and plasma technology. Moreover, Haier's CO₂ incubators, centrifuges, biosafety cabinets, and cold storage lines continue to gain market share with energy-efficient technologies tailored to local certification standards.

Automation: A Key Growth Driver

Daniele Pericolini, a European automation solutions specialist, discussed how the company intends to stimulate future growth by advancing automation in laboratories and implementing smart blood management systems. Haier's automated biobank solutions incorporate ultra-low temperature storage based on RFID technology, modular automation platforms, and liquid nitrogen systems, enhancing sample traceability and operational efficiency.

These advancements address critical challenges around sample integrity, temperature monitoring, and high-density storage, strategically positioning Haier to meet the escalating demand for advanced biobank infrastructures in Europe. Furthermore, the U-Blood intelligent blood management system shifts the paradigm from conventional refrigeration storage to a connected, real-time supply chain management solution.

Recognizing European Partnerships

The summit also highlighted successful collaborations with four partners from Germany, Slovenia, France, and Denmark, showcasing strong local validation for Haier's solutions. For instance, a long-standing partner in France presented a jointly developed biosafety cabinet tailored to French standards, with over 230 units deployed across more than 100 clients. In Denmark, Haier's ultra-low temperature freezer thrived in public tenders, while Slovenian pharmaceutical facilities demonstrated the capacity to tackle complex multi-unit projects, reinforcing Haier's reputation for reliability and adherence to regulations.

Financial Growth Amid Expansion

Haier Biomedical's expanding European footprint is underpinned by robust financial performance. In 2025, the company recorded revenues surpassing 2.3 billion RMB, with international receipts totaling 840 million RMB—accounting for more than 36% of total revenue and revealing ongoing global expansion. Europe alone experienced double-digit growth, significantly influencing Haier's overall international revenue increase. Smart automation and AI-driven solutions contributed approximately 15% to total revenue in 2025, signaling the acceleration of technology-oriented transformation.

Conclusion

Following the European Partner Summit, Haier Biomedical reaffirmed its commitment to boosting local operations, developing life science automation solutions, and fostering collaborative growth with partners. By blending global innovation capabilities with localized execution in Europe, the company aims to solidify its standing as a trusted provider of life science solutions in 2026 and beyond. For more information, visit Haier Biomedical.